Treatment of Moderate to Severe Lateral Canthal Lines
NCT04249687 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 303
Last updated 2023-06-18
Summary
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.
Conditions
- Lateral Canthal Lines
Interventions
- BIOLOGICAL
-
botulinum toxin
neuromodulator
- BIOLOGICAL
-
placebo
Sponsors & Collaborators
-
Galderma R&D
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-02-10
- Primary Completion
- 2020-09-25
- Completion
- 2021-02-10
- FDA Drug
- Yes
Countries
- United States
- Canada
Study Locations
More Related Trials
-
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
NCT03732833 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
NCT05463965 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines
NCT04143854 ·Status: COMPLETED ·Phase: PHASE2
-
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
NCT05148000 ·Status: COMPLETED ·Phase: PHASE3
-
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
NCT03721016 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
NCT02236312 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT03736928 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00968825 ·Status: COMPLETED ·Phase: PHASE2
-
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
NCT04157686 ·Status: COMPLETED ·Phase: PHASE3
-
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
NCT02677298 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
NCT02580370 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT03960957 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00968942 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)
NCT03894748 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00888914 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
NCT05217355 ·Status: COMPLETED ·Phase: PHASE2
-
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
NCT05146999 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
NCT04622254 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
NCT04143815 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
NCT05804656 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles
NCT00541723 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00884234 ·Status: COMPLETED ·Phase: PHASE2
-
Subject Satisfaction With AbobutulinumtoxinA Treatment
NCT03687736 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines
NCT05059587 ·Status: COMPLETED ·Phase: PHASE3
-
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
NCT03655691 ·Status: COMPLETED ·Phase: PHASE2